Compile Data Set for Download or QSAR
Report error Found 42 Enz. Inhib. hit(s) with all data for entry = 660
TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM168150(US9688638, 24 | US10081602, Example 24 | US1086518...)
Affinity DataEC50:  107nMAssay Description:Inhibition of cAMP accumulation by select compounds was measured in forskolin-stimulated CHO-K1 cells stably expressing KOR. CHO-K1 cells stably expr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM168148(US9688638, 20 | US10081602, Example 20 | US1086518...)
Affinity DataEC50:  6.10nMAssay Description:Inhibition of cAMP accumulation by select compounds was measured in forskolin-stimulated CHO-K1 cells stably expressing KOR. CHO-K1 cells stably expr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM168147(US9688638, 12 | US10081602, Example 12)
Affinity DataEC50:  189nMAssay Description:Inhibition of cAMP accumulation by select compounds was measured in forskolin-stimulated CHO-K1 cells stably expressing KOR. CHO-K1 cells stably expr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM168147(US9688638, 12 | US10081602, Example 12)
Affinity DataEC50:  7nMAssay Description:Inhibition of cAMP accumulation by select compounds was measured in forskolin-stimulated CHO-K1 cells stably expressing KOR. CHO-K1 cells stably expr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM285851(US10081602, Example 6 | (2S,6R,11R)-3-(Cyclopropyl...)
Affinity DataEC50:  357nMAssay Description:Inhibition of cAMP accumulation by select compounds was measured in forskolin-stimulated CHO-K1 cells stably expressing KOR. CHO-K1 cells stably expr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM285850(US10081602, Example 5 | (2S,6R,11R)-3-(Cyclopropyl...)
Affinity DataEC50:  350nMAssay Description:Inhibition of cAMP accumulation by select compounds was measured in forskolin-stimulated CHO-K1 cells stably expressing KOR. CHO-K1 cells stably expr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM285849(US10081602, Example 4 | (2S,6R,11R)-3-(Cyclopropyl...)
Affinity DataEC50:  9.35nMAssay Description:Inhibition of cAMP accumulation by select compounds was measured in forskolin-stimulated CHO-K1 cells stably expressing KOR. CHO-K1 cells stably expr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM285848(US10081602, Example 3 | (2S,6R,11R)-3-(Cyclopropyl...)
Affinity DataEC50:  122nMAssay Description:Inhibition of cAMP accumulation by select compounds was measured in forskolin-stimulated CHO-K1 cells stably expressing KOR. CHO-K1 cells stably expr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM285847(US10081602, Example 2 | (2S,6R,11R)-3-(Cyclopropyl...)
Affinity DataEC50:  139nMAssay Description:Inhibition of cAMP accumulation by select compounds was measured in forskolin-stimulated CHO-K1 cells stably expressing KOR. CHO-K1 cells stably expr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM285816(US10081602, Example 1 | (2S, 6R, 11R)-3-(Cycloprop...)
Affinity DataEC50:  153nMAssay Description:Inhibition of cAMP accumulation by select compounds was measured in forskolin-stimulated CHO-K1 cells stably expressing KOR. CHO-K1 cells stably expr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM168148(US9688638, 20 | US10081602, Example 20 | US1086518...)
Affinity DataEC50:  128nMAssay Description:Inhibition of cAMP accumulation by select compounds was measured in forskolin-stimulated CHO-K1 cells stably expressing KOR. CHO-K1 cells stably expr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM168149(US9688638, 23 | US10081602, Example 23 | US1086518...)
Affinity DataEC50:  395nMAssay Description:Inhibition of cAMP accumulation by select compounds was measured in forskolin-stimulated CHO-K1 cells stably expressing KOR. CHO-K1 cells stably expr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM168149(US9688638, 23 | US10081602, Example 23 | US1086518...)
Affinity DataEC50:  3.29E+3nMAssay Description:Inhibition of cAMP accumulation by select compounds was measured in forskolin-stimulated CHO-K1 cells stably expressing KOR. CHO-K1 cells stably expr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM168150(US9688638, 24 | US10081602, Example 24 | US1086518...)
Affinity DataEC50:  598nMAssay Description:Inhibition of cAMP accumulation by select compounds was measured in forskolin-stimulated CHO-K1 cells stably expressing KOR. CHO-K1 cells stably expr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM50027366(Ketazocine | WIN-34276 | US9688638, Ketazocine | U...)
Affinity DataEC50:  0.550nMAssay Description:Inhibition of cAMP accumulation by select compounds was measured in forskolin-stimulated CHO-K1 cells stably expressing KOR. CHO-K1 cells stably expr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM168151(US9688638, 25 | US10081602, Example 25)
Affinity DataEC50:  1.21E+3nMAssay Description:Inhibition of cAMP accumulation by select compounds was measured in forskolin-stimulated CHO-K1 cells stably expressing KOR. CHO-K1 cells stably expr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM168151(US9688638, 25 | US10081602, Example 25)
Affinity DataEC50:  195nMAssay Description:Inhibition of cAMP accumulation by select compounds was measured in forskolin-stimulated CHO-K1 cells stably expressing KOR. CHO-K1 cells stably expr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM50027366(Ketazocine | WIN-34276 | US9688638, Ketazocine | U...)
Affinity DataIC50: 5.60nMpH: 7.5Assay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM50027366(Ketazocine | WIN-34276 | US9688638, Ketazocine | U...)
Affinity DataIC50: 8.40nMpH: 7.5Assay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM285849(US10081602, Example 4 | (2S,6R,11R)-3-(Cyclopropyl...)
Affinity DataIC50: 879nMpH: 7.5Assay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM285847(US10081602, Example 2 | (2S,6R,11R)-3-(Cyclopropyl...)
Affinity DataIC50: 2.38E+3nMpH: 7.5Assay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM285816(US10081602, Example 1 | (2S, 6R, 11R)-3-(Cycloprop...)
Affinity DataIC50: 2.68E+3nMpH: 7.5Assay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM285848(US10081602, Example 3 | (2S,6R,11R)-3-(Cyclopropyl...)
Affinity DataIC50: 3.33E+3nMpH: 7.5Assay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM285851(US10081602, Example 6 | (2S,6R,11R)-3-(Cyclopropyl...)
Affinity DataIC50: 6.08E+3nMpH: 7.5Assay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM285850(US10081602, Example 5 | (2S,6R,11R)-3-(Cyclopropyl...)
Affinity DataIC50: 1.28E+4nMpH: 7.5Assay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM50027366(Ketazocine | WIN-34276 | US9688638, Ketazocine | U...)
Affinity DataKi:  1.30nMpH: 7.5Assay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM168148(US9688638, 20 | US10081602, Example 20 | US1086518...)
Affinity DataKi:  2.86nMpH: 7.5Assay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM168147(US9688638, 12 | US10081602, Example 12)
Affinity DataKi:  5nMpH: 7.5Assay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM168148(US9688638, 20 | US10081602, Example 20 | US1086518...)
Affinity DataKi:  44.3nMpH: 7.5Assay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM168147(US9688638, 12 | US10081602, Example 12)
Affinity DataKi:  58.5nMpH: 7.5Assay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM285849(US10081602, Example 4 | (2S,6R,11R)-3-(Cyclopropyl...)
Affinity DataKi:  203nMpH: 7.5Assay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM168150(US9688638, 24 | US10081602, Example 24 | US1086518...)
Affinity DataKi:  494nMpH: 7.5Assay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM285847(US10081602, Example 2 | (2S,6R,11R)-3-(Cyclopropyl...)
Affinity DataKi:  549nMpH: 7.5Assay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM285816(US10081602, Example 1 | (2S, 6R, 11R)-3-(Cycloprop...)
Affinity DataKi:  619nMpH: 7.5Assay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM285848(US10081602, Example 3 | (2S,6R,11R)-3-(Cyclopropyl...)
Affinity DataKi:  769nMpH: 7.5Assay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM168151(US9688638, 25 | US10081602, Example 25)
Affinity DataKi:  955nMpH: 7.5Assay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM168149(US9688638, 23 | US10081602, Example 23 | US1086518...)
Affinity DataKi:  1.06E+3nMpH: 7.5Assay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM285851(US10081602, Example 6 | (2S,6R,11R)-3-(Cyclopropyl...)
Affinity DataKi:  1.40E+3nMpH: 7.5Assay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM168150(US9688638, 24 | US10081602, Example 24 | US1086518...)
Affinity DataKi:  1.81E+3nMpH: 7.5Assay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM285850(US10081602, Example 5 | (2S,6R,11R)-3-(Cyclopropyl...)
Affinity DataKi:  2.96E+3nMpH: 7.5Assay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM168151(US9688638, 25 | US10081602, Example 25)
Affinity DataKi:  3.92E+3nMpH: 7.5Assay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM168149(US9688638, 23 | US10081602, Example 23 | US1086518...)
Affinity DataKi:  7.96E+3nMpH: 7.5Assay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent